Sartorius Stedim [DIM] vs Visiomed Group SA [ALVMG] Detailed Stock Comparison

Sartorius Stedim Biotech S.A.

EURONEXT
Loading...

Visiomed Group SA

EURONEXT
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Sartorius Stedim Biotech S.A. wins in 7 metrics, Visiomed Group SA wins in 8 metrics, with 0 ties. Visiomed Group SA appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Sartorius Stedim Biotech S.A. Visiomed Group SA Better
P/E Ratio (TTM) 59.45 59.67 Sartorius Stedim Biotech S.A.
Price-to-Book Ratio 3.86 N/A N/A
Debt-to-Equity Ratio 63.11 0.32 Visiomed Group SA
PEG Ratio 26.24 N/A N/A
EV/EBITDA 22.59 13.79 Visiomed Group SA
Profit Margin (TTM) 8.98% 45.95% Visiomed Group SA
Operating Margin (TTM) 19.61% 19.87% Visiomed Group SA
EBITDA Margin (TTM) 19.61% 19.87% Visiomed Group SA
Return on Equity 6.59% 3.64% Sartorius Stedim Biotech S.A.
Return on Assets (TTM) 4.14% 2.46% Sartorius Stedim Biotech S.A.
Free Cash Flow (TTM) $299.00M $-1.50M Sartorius Stedim Biotech S.A.
Dividend Yield 0.35% N/A N/A
1-Year Return 7.94% 11.11% Visiomed Group SA
Price-to-Sales Ratio (TTM) 5.29 3.85 Visiomed Group SA
Enterprise Value $17.84B $57.79M Sartorius Stedim Biotech S.A.
EV/Revenue Ratio 5.98 4.22 Visiomed Group SA
Gross Profit Margin (TTM) 41.04% N/A N/A
Revenue per Share (TTM) $31 $0 Sartorius Stedim Biotech S.A.
Earnings per Share (Diluted) $2.73 $0.00 Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A. vs Visiomed Group SA Stock Performance Analysis

Loading Price Chart...

DIM
ALVMG

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sartorius Stedim Biotech S.A.0.06%2.74%13.44%3.64%3.64%3.64%
Visiomed Group SA-3.05%5.26%5.26%11.11%11.11%11.11%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sartorius Stedim Biotech S.A.7.94%7.94%7.94%7.94%7.94%7.94%
Visiomed Group SA11.11%11.11%11.11%11.11%11.11%11.11%

Performance & Financial Health Analysis: Sartorius Stedim Biotech S.A. vs Visiomed Group SA

MetricDIMALVMG
Market Information
Market Cap i€15.79B€52.83M
Market Cap CategoryLarge capSmall cap
10 Day Avg. Volume i135,593371,925
90 Day Avg. Volume i114,562628,133
Last Close€176.50€0.19
52 Week Range€150.00 - €224.00€0.15 - €0.31
% from 52W High-21.21%-37.89%
All-Time High€551.00 (Sep 06, 2021)€173.86 (Dec 15, 2014)
% from All-Time High-67.97%-99.89%
Growth Metrics
Quarterly Revenue Growth0.02%N/A
Quarterly Earnings Growth0.03%N/A
Financial Health
Profit Margin (TTM) i0.09%0.46%
Operating Margin (TTM) i0.20%0.20%
Return on Equity (TTM) i0.07%0.04%
Debt to Equity (MRQ) i63.110.32
Cash & Liquidity
Book Value per Share (MRQ)€42.04N/A
Cash per Share (MRQ)€5.38N/A
Operating Cash Flow (TTM) i€765.70M€-1,308,000
Levered Free Cash Flow (TTM) i€262.00M€902,000
Dividends
Last 12-Month Dividend Yield i0.35%N/A
Last 12-Month Dividend i€0.69N/A

Valuation & Enterprise Metrics Analysis: Sartorius Stedim Biotech S.A. vs Visiomed Group SA

MetricDIM (Apr 26, 2026)ALVMG (Apr 11, 2026)
Price Ratios
P/E Ratio (TTM) i59.4559.67
Forward P/E i26.245.75
PEG Ratio i26.24N/A
Price to Sales (TTM) i5.293.85
Price to Book (MRQ) i3.86N/A
Market Capitalization
Market Capitalization i€15.79B€52.83M
Enterprise Value i€17.84B€57.79M
Enterprise Value Metrics
Enterprise to Revenue i5.984.22
Enterprise to EBITDA i22.5913.79
Risk & Other Metrics
Beta iN/AN/A
Book Value per Share (MRQ) i€42.04N/A

Financial Statements Comparison: Sartorius Stedim Biotech S.A. vs Visiomed Group SA

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricDIM (2025)ALVMG (2023)
Revenue/Sales i2.97B13.71M
Cost of Goods Sold i1.62B7.41M
COGS % of Revenue i54.7%54.0%
Gross Profit i1.35B6.30M
Gross Margin i45.3%46.0%
Research & Development i133.10MN/A
Operating Income (EBIT) i539.40M952,000
Operating Margin i18.2%6.9%
EBITDA i846.90M4.19M
EBITDA Margin i28.5%30.6%
Pre-Tax Income i373.20M1.52M
Pre-Tax Income % of Revenue i12.6%11.1%
Income Tax i107.30M-37,000
Income Tax % of Revenue i3.6%-0.3%
Net Income (Profit) i266.00M902,000
Profit Margin i9.0%6.6%

Balance Sheet & Liquidity Metrics

MetricDIM (2025)ALVMG (2023)
Cash & Equivalents i426.10M2.97M
Total Current Assets i1.44B5.28M
Total Current Assets % of Revenue i48.6%38.5%
Total Current Liabilities i1.41B3.38M
Total Current Liabilities % of Revenue i47.6%24.7%
Long-Term Debt i2.02B7.64M
Long-Term Debt % of Revenue i68.0%55.7%
Total Shareholders Equity i4.13B24.75M
Retained Earnings i2.65B902,000
Retained Earnings % of Revenue i89.2%6.6%
Property, Plant & Equipment i29.50M7.30M

Cash Flow Statement Comparison

MetricDIM (2025)ALVMG (2023)
Operating Cash Flow i506.30M-1.31M
Operating Cash Flow % of Revenue i17.1%-9.5%
Capital Expenditures iN/A-1.83M
Free Cash Flow i299.00M-1.50M
FCF Margin i10.1%-10.9%
Debt Repayment i-334.80M-1.29M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricDIMALVMG
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i97.30M294.17M
Float Shares i27.60MN/A
% Held by Insiders i71.50%N/A
% Held by Institutions i12.11%N/A
% Held by Public i16.39%N/A

Dividend Analysis & Yield Comparison: Sartorius Stedim Biotech S.A. vs Visiomed Group SA

MetricDIMALVMG
Last 12-Month Dividend i€0.69N/A
Last 12-Month Dividend Yield i0.35%N/A
3-Year Avg Annual Dividend i€0.94N/A
3-Year Avg Dividend Yield i0.40%N/A
3-Year Total Dividends i€2.82N/A
Ex-Dividend DateApr 02, 2025N/A